KYSA-7: A Study of Anti-CD19 CAR T-Cell Therapy, in Subjects With Refractory Primary and Secondary Progressive Multiple Sclerosis
Study sponsor: Kyverna Therapeutics
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2027-04Estimated
Enrollment · participants120Estimated
Source updated2025-01-13Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.